Maze Therapeutics (MAZE) Revenue (2024 - 2026)

Maze Therapeutics (MAZE) reported Revenue of $20.0 million for Q1 2026, up 113.11% sequentially from -$152.5 million in Q4 2024.

Maze Therapeutics (MAZE) Revenue (2024 - 2026) Analysis & Trends

Maze Therapeutics (MAZE) has 2 years of Revenue data on file, last reported at $20.0 million in Q1 2026.

For the quarter ending Q1 2026, Revenue changed N/A year-over-year to $20.0 million; the trailing twelve-month figure through Mar 2026 stood at $20.0 million (up 114.81% YoY), and the FY2024 full-year result was $15.0 million, changed N/A from the prior year.
Revenue improved to $20.0 million in Q1 2026, from -$152.5 million in the prior quarter.
In the past five years, Revenue ranged from a high of $20.0 million in Q1 2026 to a low of -$152.5 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Revenue (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	1.51 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	2.99 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	3.61 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	1.30 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Maze Therapeutics	1.49 Bn	1.49 Bn	18.21 Mn	20.00 Mn

Download Data